O N Ikediobi

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions
    Sara Correia Marques
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA, USA
    Hum Genomics 4:238-49. 2010
  2. pmc In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation
    Ogechi N Ikediobi
    Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland, USA
    Mol Cancer Ther 7:1337-46. 2008
  3. doi request reprint Somatic pharmacogenomics in cancer
    O N Ikediobi
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94118, USA
    Pharmacogenomics J 8:305-14. 2008
  4. pmc Analysis of pharmacogenetic traits in two distinct South African populations
    Ogechi Ikediobi
    University of California, San Francisco, School of Pharmacy, Department of Clinical Pharmacy, CA 94143, USA
    Hum Genomics 5:265-82. 2011
  5. pmc Addressing the challenges of the clinical application of pharmacogenetic testing
    O N Ikediobi
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, California, USA
    Clin Pharmacol Ther 86:28-31. 2009
  6. pmc Mutation analysis of 24 known cancer genes in the NCI-60 cell line set
    Ogechi N Ikediobi
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom
    Mol Cancer Ther 5:2606-12. 2006

Detail Information

Publications6

  1. pmc The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions
    Sara Correia Marques
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA, USA
    Hum Genomics 4:238-49. 2010
    ....
  2. pmc In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation
    Ogechi N Ikediobi
    Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland, USA
    Mol Cancer Ther 7:1337-46. 2008
    ..The findings reported here have potential implications for the use of phenothiazines in the treatment of V600E BRAF mutant melanoma...
  3. doi request reprint Somatic pharmacogenomics in cancer
    O N Ikediobi
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94118, USA
    Pharmacogenomics J 8:305-14. 2008
    ....
  4. pmc Analysis of pharmacogenetic traits in two distinct South African populations
    Ogechi Ikediobi
    University of California, San Francisco, School of Pharmacy, Department of Clinical Pharmacy, CA 94143, USA
    Hum Genomics 5:265-82. 2011
    ..Characterising the Xhosa and CMA population frequencies of variant alleles important for drug transport and metabolism can help to establish the clinical relevance of pharmacogenetic testing in these populations...
  5. pmc Addressing the challenges of the clinical application of pharmacogenetic testing
    O N Ikediobi
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, California, USA
    Clin Pharmacol Ther 86:28-31. 2009
    ..We discuss UGT1A1 pharmacogenetic testing to illustrate the knowledge gaps impeding widespread use of pharmacogenetic tests in the clinical setting...
  6. pmc Mutation analysis of 24 known cancer genes in the NCI-60 cell line set
    Ogechi N Ikediobi
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom
    Mol Cancer Ther 5:2606-12. 2006
    ....